Dendritic cell immunotherapy

Rachel Lubong Sabado, Nina Bhardwaj

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


The U.S. Food and Drug Administration's approval of the first cell-based immunotherapy has rejuvenated interest in the field. Early clinical trials have established the ability of dendritic cell (DC) immunotherapy to exploit a patient's own immune system to induce antitumor immune responses. However, suboptimal conditions for generating potent immunostimulatory DCs, in addition to the suppression mediated by the tumor microenvironment, have contributed to limited clinical success in vivo. Therefore, combining DC vaccines with new approaches that enhance immunogenicity and overcome the regulatory mechanisms underlying peripheral tolerance may be key to achieving effective, durable, antitumor immune responses that translate to better clinical outcomes.

Original languageEnglish
Pages (from-to)31-45
Number of pages15
JournalAnnals of the New York Academy of Sciences
Issue number1
StatePublished - May 2013
Externally publishedYes


  • Cancer
  • Dendritic cells
  • Immunotherapy
  • Vaccine


Dive into the research topics of 'Dendritic cell immunotherapy'. Together they form a unique fingerprint.

Cite this